CD4 and obesity disorder: Recently, it has been demonstrated that dASCs, from patients with obesity and T2D, retained the potential to significantly suppress CD4 T-cell proliferation, with a slightly weaker inhibitory effect than ndASCs, which was associated with significantly reduced abilities to decrease IL-2 production and increase IL-8 levels in cocultures.